Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hereditary sensory and autonomic neuropathy type 1 characterized by adult onset of a distal axonal sensory neuropathy that has material basis in heterozygous mutation in the ATL1 gene on chromosome 14q.
Features include: Peripheral axonal neuropathy, Paresthesia, Pes cavus, and Autoamputation of digits and 7 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Peripheral axonal neuropathy, Paresthesia, Peripheral neuropathy |
ATL1 encodes atlastin GTPase 1 (558 aa). Atlastin-1 (ATL1) is a membrane-anchored GTPase that mediates the GTP-dependent fusion of endoplasmic reticulum (ER) membranes, maintaining the continuous ER network. Highest expression in Brain Frontal Cortex BA9 (45.0 TPM) and Brain Cerebellar Hemisphere (34.5 TPM).
Neuropathy, hereditary sensory, type 1D is caused by mutations in the ATL1 gene on chromosome 14.
ATL1 is classified as a druggable target (Kinase category) with score 0.0.
Spastic paraplegia 3A (SPG3A; also known as ATL1-HSP) should be suspected in individuals with the following clinical findings and family history.
Clinical findings
Early age of onset, from infancy to ten years (average age: 4 years)
Progressive bilateral and mostly symmetric lower-extremity weakness and spasticity resulting from axonal degeneration of the corticospinal tracts
No approved treatments are currently available for neuropathy, hereditary sensory, type 1D. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with spastic paraplegia 3A (SPG3A; also known as ATL1-HSP), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Recommended Evaluations Following Initial Diagnosis in Individuals with Spastic Paraplegia 3A
There is no consensus regarding the frequency of clinical follow-up visits, but routine reevaluations are warranted .
Table 5.
Recommended Surveillance for Individuals with Spastic Paraplegia 3A
System/Concern | Evaluation | Frequency
| Neurologic exam re disease progression response to current treatment | 1-2x/yr
No clinical trials have been registered for neuropathy, hereditary sensory, type 1D.
6 publications have been identified in PubMed for neuropathy, hereditary sensory, type 1D. Research spans Basic Science / Preclinical (50%), Case Report / Case Series (33%), and Review / Meta-Analysis (17%).
Bertino F (2026). [PMID: 41691085](https://pubmed.ncbi.nlm.nih.gov/41691085/). *Commun Biol*. [Basic Science / Preclinical]
Bock A (2026). [PMID: 41268727](https://pubmed.ncbi.nlm.nih.gov/41268727/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Cesaroni CA (2025). [PMID: 41300731](https://pubmed.ncbi.nlm.nih.gov/41300731/). *Genes (Basel)*. [Review / Meta-Analysis]
Ahmad R (2025). [PMID: 40938507](https://pubmed.ncbi.nlm.nih.gov/40938507/). *Neurol Sci*. [Case Report / Case Series]
Cashman CR (2025). [PMID: 40400204](https://pubmed.ncbi.nlm.nih.gov/40400204/). *Ann Clin Transl Neurol*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
2 |
Autoamputation of digits, Distal lower limb amyotrophy |
Skin | 1 | Nail dystrophy |
Bones and joints | 1 | Bone infection (osteomyelitis) |
Spastic paraplegia 3A (SPG3A; also known as ATL1-HSP) is characterized by slowly progressive bilateral and mostly symmetric spasticity and weakness of the legs, and with a variable degree of diminished vibration sense (caused by degeneration of the corticospinal tracts and dorsal columns) and urinary bladder hyperactivity. The average age of onset is four years; more than 80% of affected individuals manifest spastic gait before age ten years. The rate of progression is slow; wheelchair dependency or need for an assistive walking device is relatively rare. Most persons with early-onset ATL1-HSP have a "pure" or "uncomplicated" hereditary spastic paraplegia (HSP) phenotype.
Source: GeneReviews — "Spastic Paraplegia 3A"
No specific genotype-phenotype correlations have been reported; however:
Early-onset disease has been associated with missense variants around the GTPase binding domain.
Late-onset disease has been associated with frameshift variants in the C terminus that result in premature truncation of the protein, as well as some missense variants in the GTPase binding domain .
Source: GeneReviews — "Spastic Paraplegia 3A"
Overall, penetrance of pathogenic variants is high (~80%-90%) . In many familial cases, individuals with a heterozygous ATL1 pathogenic variant had a normal neurologic examination even at an advanced age, arguing against significant age-dependent penetrance . The lowest penetrance, 30%, was reported for the heterozygous pathogenic variant detected in three affected individuals but also in nine unaffected family members . Reduced penetrance of this variant was also observed in additional families in which mostly females were unaffected, suggesting (incorrectly) X-linked inheritance .
Source: GeneReviews — "Spastic Paraplegia 3A"
Diminished vibration sense caused by impairment of dorsal columns
Urinary bladder hyperactivity
Family history consistent with autosomal dominant inheritance, including affected males and females in multiple generations and simplex cases (i.e., a single occurrence in a family). Absence of a known family history does not preclude the diagnosis.
The diagnosis of ATL1-HSP is estab...
Source: GeneReviews — "Spastic Paraplegia 3A"
Hereditary spastic paraplegia (HSP) is a progressive condition with a gradual worsening of spasticity and weakness of the lower extremities. Overall, the age of onset, disease severity, and rate of progression differ among different types of autosomal dominant (AD) HSP; there is also considerable variability within the same genetic forms of HSP. For a general discussion of the differential diagnosis of spastic paraplegia/paraparesis syndrome, see Hereditary Spastic Paraplegia Overview. ATL1 pathogenic variants have been confirmed as the most common cause of early-onset HSP, accounting for approximately 30%-50% of all AD HSP with onset before age ten years . Spastic paraplegia 3A (SPG3A; also known as ATL1-HSP) accounts for approximately 5% of all AD HSP , which is lower than previous estimates of 10%-15% . In an analysis of a large cohort of individuals in whom a SPAST (formerly known as SPG4) pathogenic variant was not identified, 40% had pathogenic variants in ATL1 . ATL1-HSP needs to be differentiated from other forms of AD HSP . Table 2. Autosomal Dominant Hereditary Spastic Paraplegias of Interest in the Differential Diagnosis of Spastic Paraplegia 3A
Gene | Disorder | Clinical Features of Differential Diagnosis Disorder1 |
|---|---|---|
KIF5A | SPG10 | Axonal motor neuropathy common2; Probably 2nd most common cause of early-onset AD HSP |
NIPA1 | SPG6 | Occasionally manifests in infancy3; Probably most aggressive form of AD HSP; wheelchair dependency in a relatively short period of time |
REEP2 | SPG72 | Early age of onset (age 4 yrs); Mild postural tremor common4 |
SLC33A1 | SPG42 | May have onset in 1st decade; Mild, minimally progressive clinical course; Pes cavus distal amyotrophy common5; Reported in a single family SPAST |
RTN2 | SPG12 | Usual onset age 10 yrs6; Uncomplicated phenotype AD HSP = autosomal dominant hereditary spastic paraplegia 1. See Hereditary Spastic Paraplegia Overview. 2. 3. 4. 5. Cerebral palsy. |
Source: GeneReviews — "Spastic Paraplegia 3A"
Genetic testing for ATL1 is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment
| Neurologic exam | Assess degree of spasticity.1
Motor sensory
neuropathy | NCV, EMG
| Physical medicine rehabilitation / PT eval | To include assessment of:
Muscle tone; joint range of motion; posture; mobility; strength, coordination, endurance; pain; bedsores
Need for adaptive devices
Footwear needs
Physical therapy needs
Orthopedics | To assess for scoliosis, foot deformities
OT | • To assess small motor function, e.g., hands, feet, face, fingers, toes
To assess ADL
| Referral to urologist; consider urodynamic eval. | To address spastic bladder symptoms: urgency, frequency, difficulty voiding
| Referral to gastroenterologist | To assess constipation fecal incontinence1
Bulbar muscle
weakness | Assessment by speech/language pathologist | • Speech disorder (dysarthria)
Swallowing disorder (dysphagia)
| By genetics professionals2 | To inform affected persons their families re nature, MOI, implications of ATL1-HSP to facilitate medical personal decision making
Family support/
resources | Assess:
Source: GeneReviews — "Spastic Paraplegia 3A"
Dantrolene should be avoided in persons who are ambulatory as it may induce irreversible weakness, which can adversely affect overall mobility.
Source: GeneReviews — "Spastic Paraplegia 3A"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Spastic Paraplegia 3A"
View trials for neuropathy, hereditary sensory, type 1D
| Per treating urologist, incl monitoring for urinary tract infection
| Gastroenterologist / nutrition / feeding team re nutrition risk for aspiration
| Per neurologic assessment speech/language assessment
| General medical exam of musculoskeletal system
| Per symptoms
| Rehabilitation medicine, PT, OT
ADL = activities of daily living; OT = occupational therapist; PT = physical therapist
Source: GeneReviews — "Spastic Paraplegia 3A"